These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 3976706)

  • 1. Post-marketing studies of drug efficacy: why?
    Strom BL; Melmon KL; Miettinen OS
    Am J Med; 1985 Mar; 78(3):475-80. PubMed ID: 3976706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating drugs after their approval for clinical use.
    Ray WA; Griffin MR; Avorn J
    N Engl J Med; 1993 Dec; 329(27):2029-32. PubMed ID: 8018139
    [No Abstract]   [Full Text] [Related]  

  • 3. Benefit and risk information in prescription drug advertising: review of empirical studies and marketing implications.
    Kopp SW; Bang HK
    Health Mark Q; 2000; 17(3):39-56. PubMed ID: 11010219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-marketing studies of drug efficacy: how?
    Strom BL; Miettinen OS; Melmon KL
    Am J Med; 1984 Oct; 77(4):703-8. PubMed ID: 6486146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are novel drugs more risky for patients than less novel drugs?
    Olson MK
    J Health Econ; 2004 Nov; 23(6):1135-58. PubMed ID: 15556240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Content and format of labeling for human prescription drugs; pregnancy labeling; public hearing--FDA. Notice of public hearing; request for comments.
    Fed Regist; 1997 Jul; 62(147):41061-3. PubMed ID: 10169832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Marketing off-label uses to physicians: FDA's draft (mis)guidance.
    Gass A; Wilson J
    Am J Bioeth; 2008 Mar; 8(3):1-3. PubMed ID: 18570084
    [No Abstract]   [Full Text] [Related]  

  • 9. U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey.
    Chen DT; Wynia MK; Moloney RM; Alexander GC
    Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1094-100. PubMed ID: 19697444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies.
    Roberts R; Rodriguez W; Murphy D; Crescenzi T
    JAMA; 2003 Aug; 290(7):905-11. PubMed ID: 12928467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Off-label or off-limits?
    Ratner M; Gura T
    Nat Biotechnol; 2008 Aug; 26(8):867-75. PubMed ID: 18688236
    [No Abstract]   [Full Text] [Related]  

  • 12. Off-label or out of bounds? Prescriber and marketer liability for unapproved uses of FDA-approved drugs.
    O'Reilly J; Dalal A
    Ann Health Law; 2003; 12(2):295-324, table of contents. PubMed ID: 12856461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA drug labeling for pregnancy and lactation drug safety monitoring systems.
    Greene MF
    Semin Perinatol; 2015 Nov; 39(7):520-3. PubMed ID: 26428020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of pediatric exclusivity on drug labeling and demonstrations of efficacy.
    Wharton GT; Murphy MD; Avant D; Goldsmith JV; Chai G; Rodriguez WJ; Eisenstein EL
    Pediatrics; 2014 Aug; 134(2):e512-8. PubMed ID: 25022732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
    Cross J; Lee H; Westelinck A; Nelson J; Grudzinskas C; Peck C
    Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):439-46. PubMed ID: 12426927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New and incremental FDA black box warnings from 2008 to 2015.
    Solotke MT; Dhruva SS; Downing NS; Shah ND; Ross JS
    Expert Opin Drug Saf; 2018 Feb; 17(2):117-123. PubMed ID: 29215916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
    Moore TJ; Furberg CD
    JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medicaid drug-event data: an emerging tool for evaluation of drug risk.
    Jones JK; Van de Carr SW; Rosa F; Morse L; LeRoy A
    Acta Med Scand Suppl; 1984; 683():127-34. PubMed ID: 6377830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomic information in FDA-approved drug labels: Application to pediatric patients.
    Green DJ; Mummaneni P; Kim IW; Oh JM; Pacanowski M; Burckart GJ
    Clin Pharmacol Ther; 2016 Jun; 99(6):622-32. PubMed ID: 26693845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.